These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22386244)

  • 1. Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.
    Liang G; Chen X; Aldous S; Pu SF; Mehdi S; Powers E; Xia T; Wang R
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2450-5. PubMed ID: 22386244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6).
    Fernández IS; Ständker L; Mägert HJ; Forssmann WG; Giménez-Gallego G; Romero A
    J Mol Biol; 2008 Apr; 377(5):1488-97. PubMed ID: 18329042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
    Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y
    Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxyanion-mediated inhibition of serine proteases.
    Presnell SR; Patil GS; Mura C; Jude KM; Conley JM; Bertrand JA; Kam CM; Powers JC; Williams LD
    Biochemistry; 1998 Dec; 37(48):17068-81. PubMed ID: 9836602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.
    Katz BA; Liu B; Barnes M; Springman EB
    Protein Sci; 1998 Apr; 7(4):875-85. PubMed ID: 9568894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors of plasma kallikrein.
    Young WB; Rai R; Shrader WD; Burgess-Henry J; Hu H; Elrod KC; Sprengeler PA; Katz BA; Sukbuntherng J; Mordenti J
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2034-6. PubMed ID: 16413183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
    Tan X; Bertonati C; Qin L; Furio L; El Amri C; Hovnanian A; Reboud-Ravaux M; Villoutreix BO
    Eur J Med Chem; 2013; 70():661-8. PubMed ID: 24211642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.
    Arama DP; Soualmia F; Lisowski V; Longevial JF; Bosc E; Maillard LT; Martinez J; Masurier N; El Amri C
    Eur J Med Chem; 2015 Mar; 93():202-13. PubMed ID: 25682203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-psi[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY-3-psi[CH2NH2+]-Asp19I.
    Bateman KS; Huang K; Anderson S; Lu W; Qasim MA; Laskowski M; James MN
    J Mol Biol; 2001 Jan; 305(4):839-49. PubMed ID: 11162096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.
    Liang G; Chen X; Aldous S; Pu SF; Mehdi S; Powers E; Giovanni A; Kongsamut S; Xia T; Zhang Y; Wang R; Gao Z; Merriman G; McLean LR; Morize I
    ACS Med Chem Lett; 2012 Feb; 3(2):159-64. PubMed ID: 24900446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation.
    Bayés A; Tsetsenis T; Ventura S; Vendrell J; Aviles FX; Sotiropoulou G
    Biol Chem; 2004 Jun; 385(6):517-24. PubMed ID: 15255184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kunitz-type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator.
    Song HK; Suh SW
    J Mol Biol; 1998 Jan; 275(2):347-63. PubMed ID: 9466914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided design of peptide-based tryptase inhibitors.
    McGrath ME; Sprengeler PA; Hirschbein B; Somoza JR; Lehoux I; Janc JW; Gjerstad E; Graupe M; Estiarte A; Venkataramani C; Liu Y; Yee R; Ho JD; Green MJ; Lee CS; Liu L; Tai V; Spencer J; Sperandio D; Katz BA
    Biochemistry; 2006 May; 45(19):5964-73. PubMed ID: 16681368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of plasma kallikrein selective inhibitors.
    Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S
    Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.
    Murafuji H; Sakai H; Goto M; Imajo S; Sugawara H; Muto T
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5272-5276. PubMed ID: 29102227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
    Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
    Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.
    Greenidge PA; Mérette SA; Beck R; Dodson G; Goodwin CA; Scully MF; Spencer J; Weiser J; Deadman JJ
    J Med Chem; 2003 Apr; 46(8):1293-305. PubMed ID: 12672230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S; Proschak E; Schneider G; Spänkuch B
    ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.